… thalidomide have been used for treating primary hepatocellular carcinoma (HCC). This
study aims to evaluate the clinical efficacy and safety of thalidomide and TACE in primary HCC. …

… of thalidomide and lenalidomide for the treatment of advanced HCC.12-14 In this open-label
phase II clinical trial… consistent with those reported in the phase 2 trial conducted in the USA.…

… In a phase II study of thalidomide in advanced HCC, activity … A retrospective analysis of
low-dose thalidomide (100 mg/day… Lenalidomide is a potent thalidomide analog with …

… In conclusion, TACE plus TLD seem useful and safe in treating patients with intermediate
or advanced HCC. However, regard the moderate to very low quality of current evidence, …

… Therefore, studies have been conducted in exploring its clinical effects in the treatment of
cancer [24,25]. This study has applied thalidomide combined with TACE to treat HCC, which …

… To first establish a baseline response in the BMOL cell lines used in this study, treatments
of 10 μM with either thalidomide, lenalidomide, pomalidomide, or sorafenib (Fig. 1) were used …

… Secondly, there is extensive evidence to support the view that some hepatocellular carcinomas
(HCC) may be derived from liver progenitor cells (LPCs) [10] and growth of these cells is …

… It is unclear whether this effect was due to lenalidomide or temsirolimus since a phase II trial
of temsirolimus with the IGF1-receptor antibody cixutumuab demonstrated stable disease >…

… Thalidomide, an … trial to assess thalidomide as an adjuvant treatment after HCC curative
resection with no definitive results yet reported [25]. We decide to prescribe it to our patient …

… effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously
… ‐label, phase II safety and efficacy clinical trial of PHY906 and capecitabine in patients with …